Mindera Health

mindera health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. mindera’s technology creates dermal intelligence™, actionable information for payers, providers and patients. the company’s flagship test, mind.px, uses both a dermal biomarker patch and machine learning to determine a patient’s receptivity to very expensive psoriasis biologics. this information is valuable to payers, who can save thousands of dollars per biologic patient using mind.px at the outset of prescription. mind.px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.